含莫西沙星方案与含左氧氟沙星方案对耐多药肺结核病的观察  

Therapeutic effects of moxifloxacin-containing protocol and levofloxicin-containing protocol on patients with multiple-drug resistant pulmonary tuberculosis

作　　者：吴树才[1] 高官聚[1] 耿书军[1] 张向丛[1] 

机构地区：[1]河北省胸科医院,石家庄市050041

出　　处：《河北医药》2012年第3期330-332,共3页Hebei Medical Journal

摘　　要：目的比较和评价含莫西沙星(MXFX)方案与含左氧氟沙星(LVFX)方案联合母牛分枝杆菌菌苗(M.vaccae)对耐多药肺结核病(MDR-PTB)的治疗效果及安全性。方法将78例痰菌阳性的MDR-PTB患者随机分成试验组(T组)与对照组(C组)每组39例,T组方案:6MDEZA(C)/12MDE、6MDEBTh/12MDE;C组方案:6VDEZA(C)/12MDE、6VDEBTh/12MDE方案。2组患者于治疗期间前6个月均加用M.vaccae,疗程结束时可评价疗效者T组33例、C组30例。结果治疗满2个月时痰菌阴转率T组为45.45%、C组为20.00%(P<0.05);治疗满4个月时痰菌阴转率T组为57.57%、C组为30.00%(P<0.05);以后各期痰菌阴转率T组均大于C组,但差异无统计学意义(P>0.05);满疗程时2组病灶吸收好转率分别为66.67%、46.67%,空洞闭合率为分别为17.24%、12.00%,2组比较差异无统计学意义(P>0.05)。不良反应:T组为30.76%(12/39),C组为38.46%(15/39),差异无统计学意义(P>0.05)。结论莫西沙星对MDR-PTB的治疗是有效且安全的。Objective To compare and evaluate the therapeutic effect and safety of moxifloxaein- containing protocol and levofloxiein-containing protoeol in patients with multiple-drug resistant pulmonary tuberculosis（MDR-PTB）. Methods 70 patients with MDR-PTB whose sputum euhures were positive were randomly divided into trial group （ n = 39 ）and control group （ n = 39 ）. The treatment protocol of trial group was 6MDEZA （c）/i2MDE, 6MDEBTh/12MDE, however, whieh in control group was 6VDEZA （C）/12MDE, 6DVEBTh/12MDE. The patients in both groups were administrated with M. vaeeae in the initial 6 months. The therapeutie effects were evaluated at the end of treatment course for 33 patients in trial group and 30 patients in control group. Results At the end of 2 months after treatment, the sputum negative conversion rate in trial group was 45.45 %, however, which in eontrol group was 20.00%, there was a significant difference between two groups （ P 〈 0.05 ） ; at the end of 4 months after treatment, the sputum negative conversion rate in trial group was 57.57% ,however, which in control group was 30. 00%, there was a signifieant difference between two groups （ P 〈 O. 05 ）. The sputum negative conversion rates in trial group at latter periods were higher than those in control group,but there was no significant difference between two groups （ P 〉 0.05 ）. At the end of treatment course,the focus absorption improvement rates in trial group and control group were 66.67% ,46.67%, respectively, cavity closing rates were 17.24%, 12.00%, respectively, and there were no significant differences between two groups （ P 〉 0.05 ）. The ineidenee of adverse reaetion ： it in trial group was 30.76% （ 12/39 ）, and it in eontrol group was 38.46% （15/39）, and there were no significant differences between two groups （ P 〉 0.05 ）. Conclusion The moxifloeaein is effeetive and safe in the treatment of MDR-PTB.

关 键 词：结核 肺 各种药物疗法 抗药性 多药 

分 类 号：R521[医药卫生—内科学]